StrokeDx develops advanced technologies and software to enable portable, non-invasive, non-radiating cerebrovascular monitoring. Its approach offers a unique and highly precise method to survey strokes using next-generation technology developed by Shane Shahrestani, MD, PhD, at Caltech. The company positions its portable devices as a scalable solution to improve stroke outcomes and to address healthcare accessibility and equity. StrokeDx says early detection and rapid monitoring can shift focus from treatment to prevention and improve survival and quality of life. The company announced an oversubscribed $5 million Series Seed Prime to support further clinical validation and to expand its commercial efforts. To date, StrokeDx’s technology has raised almost $10 million, including a National Institutes of Health R01 grant.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

May 2024